Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SST-1034
- Development stage
- Preclinical
- Lead developer
- StemSynergy Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
SST-1034 is a small-molecule activator of casein kinase 1 alpha (CK1α) being developed by StemSynergy Therapeutics as a targeted therapy for Wnt pathway–dependent diseases and tumors, including adenomatous polyps.[7][5][12] By selectively activating CK1α, a key negative regulator of canonical Wnt/β‑catenin signaling, SST-1034 is intended to enhance phosphorylation and degradation of β‑catenin, thereby suppressing oncogenic Wnt-driven transcriptional programs in susceptible tissues.[7][5] The program remains in preclinical development, with no disclosed clinical trials or marketed formulations to date.[7][5][12]
02
Targets
CK1α (Casein kinase I alpha)
Beyond the preview
Go deeper on SST-1034.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SST-1034.